Biosimilar Product Information
Topics: Legal / Regulatory
106 Results
Biosimilar medicines uptake: The role of the clinical pharmacist
Topics: Implementation
Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
Topics: Rheumatology
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
Topics: Implementation, P&T Committee
The Complexities of Biosimilars and the Regulatory Approval Process
Topics: Legal / Regulatory
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
Topics: Rheumatology
Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations
Topics: Medication Use Evaluation (MUE)
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence
Topics: Rheumatology
Best Practices in Multiple Sclerosis Therapies
Topics: Multiple Sclerosis
Biosimilars – Providing Affordable, Accessible Care for Patients
Topics: Economics, Implementation
Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System
Topics: Implementation
Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
Topics: Implementation
Cost Savings with Biosimilars in Rheumatology: A Systematic Literature Search of Budget Impact Analysis
Topics: Economics
Implementation Strategies of Biosimilars in Healthcare Systems: The Path Forward
Topics: Implementation
Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
Topics: Rheumatology
OBSIDIAN – real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis
Topics: Rheumatology
Biosimilars (National Psoriasis Foundation)
Topics: Rheumatology
Position Statement on the Use of Biosimilars for Psoriasis and Psoriatic Arthritis
Topics: Rheumatology
Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis
Topics: Rheumatology
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
Topics: Rheumatology
Page 3 of 6